CY1123916T1 - Συνδυασmος που περιλαμβανει mιa ενωση αμινοθειολεστερα ή ενα φαρμακευτικως αποδεκτο αλας αυτης και mιa ενωση ικανη αυξησης του επιπεδου η2ο2 στα καρκινικα κυτταρα ενος υποκειμενου - Google Patents

Συνδυασmος που περιλαμβανει mιa ενωση αμινοθειολεστερα ή ενα φαρμακευτικως αποδεκτο αλας αυτης και mιa ενωση ικανη αυξησης του επιπεδου η2ο2 στα καρκινικα κυτταρα ενος υποκειμενου

Info

Publication number
CY1123916T1
CY1123916T1 CY20211100174T CY211100174T CY1123916T1 CY 1123916 T1 CY1123916 T1 CY 1123916T1 CY 20211100174 T CY20211100174 T CY 20211100174T CY 211100174 T CY211100174 T CY 211100174T CY 1123916 T1 CY1123916 T1 CY 1123916T1
Authority
CY
Cyprus
Prior art keywords
subject
compound
pharmaceutically acceptable
acceptable salt
cancer cells
Prior art date
Application number
CY20211100174T
Other languages
English (en)
Inventor
Ismail Ceylan
Gerry QUASH
Mileidys PEREZ-ALEA
Guillaume Martin
Original Assignee
Advanced Biodesign
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Biodesign filed Critical Advanced Biodesign
Publication of CY1123916T1 publication Critical patent/CY1123916T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Συνδυασμός που περιλαμβάνει μια ένωση αμινοθειολεστέρα ή ένα φαρμακευτικώς αποδεκτό άλας αυτής και μια ένωση ικανή αύξησης του επιπέδου Η2Ο2 στα καρκινικά κύτταρα ενός υποκειμένου, προς χρήση ως ένα φάρμακο. Η παρούσα εφεύρεση αναφέρεται σε έναν συνδυασμό που περιλαμβάνει μια ένωση αμινοθειολε-στέρα ή ένα φαρμακευτικώς αποδεκτό άλας αυτής, συγκεκριμένα το 4-(διμεθυλαμινο)-4-μεθυλπεντ-2-υνο-θειοϊκό S-μεθύλιο ή ένα φαρμακευτικώς αποδεκτό άλας αυτού, και πιο συγκεκριμένα το φουμαρικό S-μεθυλεστέρα 4-(Διμεθυλαμινο)-4-μεθυλ-2-πεντυνοθειοϊκού οξέος, και μια ένωση ικανή αύξησης του επιπέδου Η2Ο2 στα καρκινικά κύτταρα ενός υποκειμένου, ιδιαίτερα προς χρήση για τη θεραπευτική αγωγή καρκίνου σε ένα υποκείμενο, όπου τα καρκινικά κύτταρα του ρηθέντος υποκειμένου δεν υπερπαράγουν Η2Ο2 συγκριτικά με μια τιμή ελέγχου και έχουν ένα επίπεδο GSH κάτω από 5 nmol για 25000 κύτταρα.
CY20211100174T 2015-10-15 2021-03-02 Συνδυασmος που περιλαμβανει mιa ενωση αμινοθειολεστερα ή ενα φαρμακευτικως αποδεκτο αλας αυτης και mιa ενωση ικανη αυξησης του επιπεδου η2ο2 στα καρκινικα κυτταρα ενος υποκειμενου CY1123916T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15306650 2015-10-15
PCT/EP2016/074682 WO2017064241A1 (en) 2015-10-15 2016-10-14 Combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof and a compound able to increase the h2o2 level in cancer cells of a subject

Publications (1)

Publication Number Publication Date
CY1123916T1 true CY1123916T1 (el) 2022-05-27

Family

ID=54360386

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100174T CY1123916T1 (el) 2015-10-15 2021-03-02 Συνδυασmος που περιλαμβανει mιa ενωση αμινοθειολεστερα ή ενα φαρμακευτικως αποδεκτο αλας αυτης και mιa ενωση ικανη αυξησης του επιπεδου η2ο2 στα καρκινικα κυτταρα ενος υποκειμενου

Country Status (21)

Country Link
US (1) US10406125B2 (el)
EP (1) EP3362094B1 (el)
JP (1) JP7062592B2 (el)
CN (1) CN108348612A (el)
AR (1) AR106351A1 (el)
CA (1) CA3001201C (el)
CY (1) CY1123916T1 (el)
DK (1) DK3362094T3 (el)
ES (1) ES2870508T3 (el)
HK (1) HK1251477A1 (el)
HR (1) HRP20210358T1 (el)
HU (1) HUE054247T2 (el)
IL (1) IL258658B (el)
LT (1) LT3362094T (el)
MX (1) MX2018004381A (el)
PL (1) PL3362094T3 (el)
PT (1) PT3362094T (el)
RS (1) RS61572B1 (el)
SI (1) SI3362094T1 (el)
WO (1) WO2017064241A1 (el)
ZA (1) ZA201802400B (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220039722A (ko) * 2019-07-31 2022-03-29 어드방스드 비오디자인 아미노티올에스터 화합물 및 이의 용도
FR3119314A1 (fr) * 2021-01-29 2022-08-05 Advanced Biodesign Nanocapsule lipidique comprenant au moins un composé aminothiolester ou un de ses dérivés pharmaceutiquement acceptable
EP4035666A1 (en) * 2021-01-29 2022-08-03 Advanced Biodesign Aminothiolester compound or derivative thereof for use as an immunomodulatory agent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777001B1 (fr) * 1998-04-01 2000-06-09 Cird Galderma Derives de l'acide 6,8-dimercaptooctanoique substitues en 6-s et/ou en 8-s par le radical (3-methylthiopropanoyl) et compositions pharmaceutiques destinees au traitement des tumeurs cancereuses
FR2809727B1 (fr) 2000-05-31 2002-07-26 Galderma Res & Dev Nouveaux composes aminothiolesters, compositions pharmaceutiques et cosmetiques les contenant et utilisations

Also Published As

Publication number Publication date
MX2018004381A (es) 2018-05-11
CA3001201C (en) 2023-07-11
ZA201802400B (en) 2020-01-29
CN108348612A (zh) 2018-07-31
EP3362094B1 (en) 2021-02-17
DK3362094T3 (da) 2021-03-01
US20180303773A1 (en) 2018-10-25
US10406125B2 (en) 2019-09-10
SI3362094T1 (sl) 2021-04-30
LT3362094T (lt) 2021-05-10
EP3362094A1 (en) 2018-08-22
JP7062592B2 (ja) 2022-05-06
HK1251477A1 (zh) 2019-02-01
IL258658A (en) 2018-06-28
WO2017064241A1 (en) 2017-04-20
JP2018531995A (ja) 2018-11-01
HRP20210358T1 (hr) 2021-04-16
IL258658B (en) 2021-04-29
HUE054247T2 (hu) 2021-08-30
PL3362094T3 (pl) 2021-10-11
BR112018007480A2 (pt) 2018-10-23
RS61572B1 (sr) 2021-04-29
AR106351A1 (es) 2018-01-03
PT3362094T (pt) 2021-04-15
ES2870508T3 (es) 2021-10-27
CA3001201A1 (en) 2017-04-20

Similar Documents

Publication Publication Date Title
CY1123916T1 (el) Συνδυασmος που περιλαμβανει mιa ενωση αμινοθειολεστερα ή ενα φαρμακευτικως αποδεκτο αλας αυτης και mιa ενωση ικανη αυξησης του επιπεδου η2ο2 στα καρκινικα κυτταρα ενος υποκειμενου
CY1124592T1 (el) Ζιζανιοκτονως δραστικα 3-φαινυλοïσοξαζολινο-5-καρβοξαμιδια αποτελουμενα απο τετραϋδρο- και διυδροφουρανοκαρβοξυλικα οξεα και εστερες
CO2017005038A2 (es) Composicones y métodos de tratamiento con profármacos de tizoxanida, un análogo o sal de la misma
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
CY1119707T1 (el) Ενωσεις διαρυλικου αμιδιου ως αναστολεις της κινασης
CY1119771T1 (el) Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak
CO2018011064A2 (es) Inhibidores de bromodominios
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
CO2021006075A2 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
EA201792116A1 (ru) Ингибитор янус-киназы
UA118149C2 (uk) Інгібітор jak
CY1123963T1 (el) Καινοτομα πολυμερικα προφαρμακα hgh
CY1123947T1 (el) Βελτιστοποιημενος υποκινητης rpe65 και βελτιστοποιημενες κωδικοποιητικες αλληλουχιες
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
BR112017000730B8 (pt) Derivados de pirrolidinona como inibidores de metap-2, e medicamentos
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
MX2020001875A (es) Forma polimorfica de tg02.
EA201890906A1 (ru) ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
CY1123950T1 (el) Αμινοθειολεστερικες ενωσεις ή φαρμακευτικως αποδεκτα αλατα αυτων, για χρηση στην αντιμετωπιση καρκινου
CY1120432T1 (el) Παραγωγα του φωσφοραμιδικου οξεος του 5-[5-φαινυλ-4-(πυριδιν-2-υλομεθυδαμινο)κιναζολιν-2-υλ]πυριδινο-3-σουλφοναμιδιου
CY1124229T1 (el) Συνδυασμος τραζοδονης και γκαμπαπεντινης για την αντιμετωπιση του πονου
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
PH12018500967B1 (en) Soy sauce-like seasoning